Shirin David

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

Retrieved on: 
Thursday, April 25, 2024
PFS, Shirin David, JAMA, Risk, NDA, Government, Progression-free survival, New Drug Application, American Medical Association, Cisplatin, Death, Immunotherapy, Trial of the century, ASCO, European, Health department, Dor, Patient, Nasopharyngeal carcinoma, Society, NPC, Marketing, Clutch (eggs), Journal, Pharmaceutical industry

Toripalimab plus chemotherapy also reduced the risk of disease progression or death by 48% and the risk of death by 37%, all while demonstrating a manageable safety profile.

Key Points: 
  • Toripalimab plus chemotherapy also reduced the risk of disease progression or death by 48% and the risk of death by 37%, all while demonstrating a manageable safety profile.
  • So far, toripalimab has been approved for marketing in the Chinese mainland and the US.
  • Several NDAs are currently under regulatory review in the European Union, UK, Australia, Singapore, Malaysia and Hong Kong Special Administrative Region (“SAR”).
  • Furthermore, NDAs for toripalimab have also been submitted in India, South Africa, Chile and Jordan.

Dropbox 2024 Spring Release: Introducing Seamless End-to-end Encryption, Microsoft Co-Authoring, New Dropbox Replay Features, and More

Retrieved on: 
Wednesday, April 24, 2024
Software, Artificial Intelligence, Data Management, Professional Services, Technology, Online Privacy, Security, Business, Cloud, Shirin David, Virtual, IP, Zendesk, Risk, AI, Microsoft Excel, AVID, Machine learning, Trust, Research, PDF, Microsoft PowerPoint, OneDrive, Knowledge, Foot, PSD, First officer (aviation), Stack, Microsoft, Privacy, FIPS, Enterprise, Home page, Create, Business Plus, Microsoft OneNote, Online shopping

So today, Dropbox is adding even more advanced data protection features, designed to be easy-to-use for all business teams.

Key Points: 
  • So today, Dropbox is adding even more advanced data protection features, designed to be easy-to-use for all business teams.
  • The latest security features will be available to all Dropbox Advanced, Business Plus, and Enterprise customers starting today.
  • Today, Dropbox is building on this with even more Microsoft integrations designed to simplify work for customers.
  • Dropbox Replay for OneDrive: Bring media files from OneDrive directly into Dropbox Replay for reviews and approvals.

STALICLA Appoints Dr. Thomas Blaettler, MD

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, FDA, Shirin David, University, Central nervous system disease, PNAS, Neuroscience, Maas, Neurodevelopmental disorder, Phase II, CNS, Roche, CFDA, Novartis, Science, Patient, EMA, Initial public offering, Multimedia, BMS, Drug development, Medicine, PMDA, Myenteric plexus, Pharmaceutical industry

STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer.

Key Points: 
  • STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240411118139/en/
    Thomas Blaettler, MD, joins STALICLA as Chief Medical Officer.
  • (Photo: Business Wire)
    Dr. Thomas Blaettler brings a wealth of pharmaceutical development experience and deep insights to help progress STALICLA’s ambitions in CNS conditions.
  • Thomas has profound regulatory experience across the globe (EMA, FDA, PMDA, CFDA) from pre-IND interaction to submissions of NDAs and MAAs.

Concentric AI Launches Industry’s First AI-enabled Data Detection and Response Protecting Organizations in Employee Offboarding Scenarios

Retrieved on: 
Wednesday, April 10, 2024
Data Management, Security, Technology, Software, Networks, Artificial Intelligence, Internet, Salesforce, Shirin David, Ecosystem, IP, Risk, Artificial intelligence, Gen, Classification, Workforce, BigQuery, Software design, API, Concentric objects, Organization, Deep learning, Medical device

As organizations experience employee churn, ensuring that data is protected and employees don’t leave with sensitive IP is critical.

Key Points: 
  • As organizations experience employee churn, ensuring that data is protected and employees don’t leave with sensitive IP is critical.
  • Employee offboarding presents unique challenges for data security, especially with a workforce that’s heavily cloud-driven and more remote than ever before.
  • “This new functionality is a result of our customers’ requests as they deal with offboarding employees and potential data loss.
  • Concentric AI’s Semantic Intelligence DSPM solution scans organizations’ data, detects sensitive or business critical content, identifies the most appropriate classification category, and automatically tags the data.

Crown Castle Issues Open Letter to Shareholders

Retrieved on: 
Monday, March 25, 2024
Sprint, BofA Securities, Tax, Verizon Communications, Letter, Ted, File, Face, Exercise, CFO, Name, Shirin David, Shareholder, Strategic planning, Integration, Sale, CCI, Motion, Security (finance), Senior, Outline, Morgan Stanley, REIT, Person, T-Mobile, Boots (company), Interim, Telecommunications, American Tower, Family, CTIA, Consultant, Annual general meeting

HOUSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today filed its preliminary proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its 2024 Annual Meeting of Stockholders to be held on May 22, 2024.

Key Points: 
  • The Crown Castle Board of Directors unanimously recommends shareholders use the WHITE proxy card to vote FOR only the twelve nominees proposed by our Board of Directors.
  • The Board values feedback from all of its shareholders, and as we advance these initiatives, we are committed to acting in our shareholders’ best interests by positioning Crown Castle for long-term success and value creation.
  • Crown Castle today is very different than it was 22 years ago when Mr. Miller was last at the Company.
  • Boots Capital’s proposal does not create any actual tax “savings” to Crown Castle, because Crown Castle is a REIT and does not pay taxes as long as it pays distributions to shareholders equal to its taxable income each year.

SilverBow Resources Highlights Successful Implementation of Strategy and Positive Business Momentum

Retrieved on: 
Thursday, March 28, 2024
Oil, Gas, Energy, Inclusion, Letter, Growth, Shirin David, Partnership, ALL, History, NDA, Acquisition, Interview, ROCE, Investment, System, KTG, NOT, Chevron Corporation, Annual general meeting, Audit committee, Management

SilverBow has been successfully implementing our strategy of building a scalable and durable portfolio, driving efficiencies and enhancing margins, protecting the balance sheet, and delivering profitable growth.

Key Points: 
  • SilverBow has been successfully implementing our strategy of building a scalable and durable portfolio, driving efficiencies and enhancing margins, protecting the balance sheet, and delivering profitable growth.
  • From 2020 to 2023, we have more than doubled our portfolio to approximately 1,000 gross locations across 220,000 acres.
  • Our strategy has proven to be resilient through market cycles and has delivered significant shareholder value, with total shareholder returns of more than 550% since 2021.
  • Our results are telling a clear story of the positive momentum in our business.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 20, 2024
Shift, Acquisition, DSM-IV codes, Fibromyalgia, Central nervous system, Total, New Drug Application, MD, Narcolepsy, FDA, Marketing, Smoking, Food, Somnolence, Growth, SYMPHONY, Reboxetine, Psychiatry, Dextromethorphan/bupropion, Migraine, FOCUS, Safety, Therapy, Medicare, NMDA, CNS, Food and Drug Administration, BED, Webcast, Depression, Binge eating disorder, Patient, Agitation, Shirin David, Medicaid, SWD, Breakthrough therapy, MDD, NDA, Prescription, Pharmaceutical industry

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.

Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer

Retrieved on: 
Wednesday, February 21, 2024
FDA, Health, General Health, Pharmaceutical, Cardiology, Biotechnology, Division, Multimedia, Unstable angina, MD, Drug development, Risk, Safety, Therapy, Nephrology, Disease, Percutaneous coronary intervention, Patient, Acute kidney injury, AKI, Shirin David, Trimetazidine, IND, Mortality, Circulatory system, PCI, Pharmaceutical industry

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer.

Key Points: 
  • Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer.
  • Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA.
  • His guidance and his wealth of regulatory experience in the cardio-renal area at the FDA will tremendously benefit our mission to bring ST-62516 to patients,” said Anna Kazanchyan, MD, Founder and CEO of Saghmos.
  • ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI.

Contract Logix Recognizes Trailblazers in Digital Contract Transformation (DCX), Announcing 2023 DCX Award Winners

Retrieved on: 
Tuesday, March 5, 2024
Hospital, Winners, Assistant, Marketing, Quality of life, Digital, Accountable care organization, Overalls, Risk, ACH, Medicare, DCX, Organization, Patient, Patent, Shirin David, CLM, Paralegal, Devlin, Software, Workflow, Nursing

LOWELL, Mass., March 5, 2024 /PRNewswire-PRWeb/ -- Contract Logix, a leading provider of data-driven contract management software, today announced the Winners, Runners-Up, and Finalists of its 2023 Digital Contract Transformation (DCX) Awards. These organizations and individuals were recognized for driving commitment to contract lifecycle management (CLM) and for evangelizing how DCX can have a significant positive impact on business processes, as well as improving collaboration, mitigating risk, increasing compliance, and finalizing business faster.

Key Points: 
  • Customer Awards Program Celebrates Individuals and Organizations Digitally Transforming Contract Lifecycle Management into an Intelligent, Automated, and Data-Driven Function
    LOWELL, Mass., March 5, 2024 /PRNewswire-PRWeb/ -- Contract Logix, a leading provider of data-driven contract management software , today announced the Winners, Runners-Up, and Finalists of its 2023 Digital Contract Transformation (DCX) Awards .
  • The Digital Contract Transformation Awards program is another way Contract Logix recognizes the innovative and creative ways our valued customers use our platform.
  • Digital Contract Transformation of the Year Award – Organizational Category:
    WINNER - American Choice Healthcare (ACH) for dramatic improvements in streamlining and automating its contracting processes to deliver improved reporting, visibility, and efficiency.
  • CovationBio's entire contract process is now automated across the entire lifecycle, from the contract request submission to third-party execution.